Avenue Therapeutics, Inc.

OTC: ATXI · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001644963Reports USD

#830 of 1,394 Healthcare companies by revenue

EA Score

25D

FH 33DQ 12GM —SS 26

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, listing tenure · ↓ disclosure history, workforce scale

Methodology →

Revenue TTM

$1.4M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.9M

Employees

Market cap

$1.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.4M$1.4M2025

Net income-$2.9M-$2.9M2025

Operating income-$3.1M-$3.1M2025

Total assets$2.9M$2.9M2025

Liabilities$1.1M$1.1M2025

Equity$1.8M$1.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Avenue Therapeutics, Inc. booked $1.4M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -207.2% net margin.

Peers · Healthcare

Stella Diagnostics Inc.——Suvanza Pharma, LLC——Hepion Pharmaceuticals, Inc.25D EVIO, Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B60C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B56C

Key facts

CEOAlexandra MacLean

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeOTC: ATXI

Employees2

IPO date2017-06-27

Latest filings

10-Q2026-05-08 10-K2026-03-30 8-K2026-02-23 8-K2025-12-31 DEF 14A2025-12-05 8-K2025-11-18 10-Q2025-11-13 8-K2025-11-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.